In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...
- Large, Randomized Controlled ADVENT Trial Designed to Establish New Gold Standard for AF Ablation - MENLO PARK, Calif., Dec. 17, 2020/CNW/ - FARAPULSE Inc. ("FARAPULSE" or "the Company") today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results